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Abstract
Purpose The use of ADHD drugs among adults is controver-
sial and has until recently not been approved for use in adults
in most countries. The aim was to investigate use of ADHD
drugs (stimulants and atomoxetine) among the entire adult
population in the Nordic countries.
Methods We conducted a multinational population-based pre-
scription register study based on the entire adult population in
the five Nordic countries (Denmark, Finland, Iceland, Norway
and Sweden). All users of ADHD drugs aged 18–64 years
during 2008–2012 were included, which for 2012 comprised
76,896 drug users among 15.8 million adult inhabitants.
Results Annual prevalence of drug use increased during the
study period for both genders and all age groups. The overall
prevalence increased from 2.4 to 5.3 per 1000 men and 1.8 to
4.4 per 1000 women. Incidence also increased, but to a lesser
extent in the last part of the study period. Methylphenidate
was used by 88 % of drug users. Treatment was discontinued
within the first year by 21 % of new drug users. Among all
users of ADHD drugs, 53 % of men and 64 % of women
concurrently used other psychotropic drugs, most frequently
antidepressants and hypnotics. Psychotropic co-medication
increased with age and was more pronounced among women
than men.
Conclusions Use of ADHD drug among adults more than
doubled over a 5-year period, and a majority were concurrent-
ly treated with other psychotropics. Adults constitute a sub-
stantial proportion of persons treated with ADHD drugs.
Thus, evidence for long-term efficacy and safety in adults is
urgently needed.
Keywords ADHD . Psychostimulants . Adults .
Pharmacoepidemiology . Nordic countries
Introduction
The diagnosis of attention-deficit hyperactivity disorder
(ADHD) among adults is controversial [1–4]. Nevertheless,
evidence shows that symptoms of ADHD may persist into
adulthood in a substantial proportion of child and adolescent
patients [5–11]. The prevalence estimates of ADHD in adults
are reported to be between 1 and 8 % [9], with variation by
geographic region, diagnostic system used and underlying
study population [6, 9, 12–14]. Adults with ADHD have a
high degree of psychiatric comorbidity, complicating diagnos-
tics as well as treatment [6, 15]. While physicians have previ-
ously had little guidance for diagnosing and treating adult
ADHD, adults have been included in recent guidelines [8,
16–19], reflecting the increasing awareness of ADHD symp-
toms beyond childhood. However, until recently, atomoxetine
was the only drug approved for use in adults [8, 9], which
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reflects that long-term efficacy and safety of these drugs are
insufficiently studied in adults [20–22]. Despite these consid-
erations, use of ADHD drugs among adults has increased
rapidly throughout the world [14, 23–26]. To ensure rational
use of stimulants and other ADHD drugs in the adult popula-
tion, detailed knowledge on utilization patterns is thus urgent-
ly needed. Leveraging high-quality prescription register data
available in the five Nordic countries, we aimed to describe
the use of stimulants and atomoxetine in the adult population.
Method
Study setting, population and data sources
This population-based study examines the use of ADHD
drugs among adults aged 18–64 years in ambulatory care in
all five Nordic countries (Denmark, Finland, Iceland, Norway,
Sweden), comprising in total 15.8million inhabitants in this age
range. Data on prescription drugs dispensed from pharmacies
were retrieved from the nationwide prescription registers in
each country [27]. Data on filled prescriptions are sent elec-
tronically from all pharmacies to the national registers.
Reporting to the registers is mandatory, ensuring high cover-
age of prescription drug use in the ambulatory care setting.
These registers allow individual-level drug use to be tracked
over time by using the unique personal identity number
(encrypted) assigned to all citizens [27].
The number of inhabitants in each country by gender and
age group was retrieved from national population registers
(Social Insurance Institution (Kela) in Finland and the bureau
of statistics in the other countries). In 2012, the number of
inhabitants aged 18–64 years was as follows: 3.4 million in
Denmark, 3.3 million in Finland, 199,000 in Iceland, 3.1 mil-
lion in Norway and 5.8 million in Sweden (total 15.8 million).
ADHD drugs
Medical products in the Nordic countries are classified ac-
cording to the Anatomical Therapeutic Chemical (ATC) clas-
sification system [28]. For the present study, ADHD drugs
were defined as methylphenidate (ATC code N06BA04),
atomoxetine (N06BA09), amphetamine (N06BA01) and
dexamphetamine (N06BA02). Methylphenidate was further
classified in extended release (ER) and immediate release
(IR) formulations. Danish data did not include amphetamine,
which is not marketed and thus rarely used in Denmark.
Data analysis
Prescription data from each country were uploaded to a server
at Statistics Denmark and analysed by a common programme
in Stata version 13. Drug utilization was measured during
2008–2012, whereas data from 2006 to 2007 were used in
specific analyses as a run-in period to define new users of
ADHD drugs. Results are presented by gender and age
attained at the start of the year by four age groups (18–24,
25–34, 35–44 and 45–64 years), combined for all Nordic
countries (main results) and by country (Online Resource).
ADHD drug use was examined using the following
definitions.
Prevalence: Annual prevalence proportion (per 1000) of
ADHD drug use was defined as the number of individ-
uals who filled at least one prescription in one calendar
year divided by the gender- and age-specific population
of the same year.
Incidence: Annual incidence (per 1000) of ADHD drug use
was defined as the number of individuals who filled at least
one prescription in one calendar year, and with no prescrip-
tion fills during the previous 2 years (730 days), divided by
the gender- and age-specific population of the same year.
Type of ADHD drug used at treatment initiation: The type
of ADHD drugs received at treatment initiation (i.e. first
prescription fill) was assessed among new users during
2008–2012. New users were defined as individuals that
had not previously filled any prescription for ADHD
drugs (going back to 2006).
Early discontinuation and switch in drug treatment:
Among new users of ADHD drugs (defined as above),
early discontinuation of treatment was defined as filling
no more than two prescriptions for ADHD drugs during
the first year (365 days) after initiating treatment.
Prescriptions filled on the same date were counted as on
prescription. Early switch in treatment was assumed if an
individual who initiated treatment with methylphenidate
filled a subsequent prescription for atomoxetine during
the first year, or vice versa. In this analysis, users initiat-
ing treatment in 2012 were disregarded to ensure 1 year
of prescription data follow-up.
Co-medication with other psychotropic drugs: Use of
other types of psychotropic drugs was examined among
prevalent users of ADHD drugs. For all individuals who
filled a prescription for an ADHD drug in one calendar
year, the proportion (%) that filled prescriptions for other
psychotropic drugs concurrently [29] with an ADHD
drug (within 3 months) was calculated. Other psychotro-
pic drugs were classified as antipsychotics (ATC N05A),
anxiolytics (N05B), hypnotics and sedatives (N05C), an-
tidepressants (N06A) and antiepileptics (N03A).
Ethical approval
Personal identity numbers were encrypted. In accordance with
laws and regulations, no ethical approval is needed for use of
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the Danish, Finnish and Norwegian prescription register da-
ta. The study was approved by the Icelandic Bioethics
Committee (VSNb2013010018/03.07) and the Icelandic
Data Protection Authority (2013010062TS/–), and in
Sweden, it was approved by the the Karolinska Institutet
regional ethics committee.
Results
The source population was the Nordic population aged 18–
64 years. In 2012, this comprised 15,828,232 inhabitants,
with 5.3 per 1000 men (n = 42,450), 4.4 per 1000 women
(n = 34,446) and 4.9 per 1000 in total (n = 76,896) filling a
prescription for ADHD drugs.
Prevalence
The highest prevalence of ADHD drug use in 2012 was
among 18-year olds at 17.2 per 1000 men and 12.8 per 1000
women (Fig. 1). Prevalence decreased with age in both gen-
ders. Substantial differences in prevalence were observed be-
tween countries (Online Resource Fig. S 1), with the highest
prevalence in Iceland and the lowest in Finland (e.g. 25.2
versus 5.3 per 1000 among 18-year-old men).
From 2008 to 2012, the prevalence of ADHD drug use
more than doubled in all gender and age categories (Fig. 2
and Online Resource Table S1), from 2.4 to 5.3 per 1000
men and from 1.8 to 4.4 per 1000 women aged 18–64 years.
Thus, over the study period, the male/female ratio decreased
from 1.33 to 1.20. Country-specific analyses showed increas-
ing prevalence for all gender and age categories in all coun-
tries except Finland (Online Resource Fig. S2 and Table S1).
The prevalence more than doubled in Iceland, Denmark and
Sweden, while the increase in Norway was more modest.
Methylphenidate was the predominant drug dispensed, as it
was used by 87–88 % of ADHD drug users in all age groups
and both genders throughout the study period. A shift was
observed from use of immediate release (IR) to extended re-
lease (ER) methylphenidate formulations; 64 vs 73 % of users
received ER formulations in 2008 and 2012, respectively,
while IR formulations decreased from 41 to 34 % in the same
period. The proportion using atomoxetine remained stable at
12–14 %, while less than 5 % used amphetamine and
dexamphetamine.
Incidence
The annual incidence of ADHD drug use increased modestly
among all age groups and both genders during the study peri-
od, and mainly in 2008–2010 (Fig. 3). The changes in inci-
dence over time varied by country, rising the most in Iceland
and to a lesser extent in Denmark and Sweden, while remain-
ing stable in Finland and Norway (Online Resource Fig. S3).
Fig. 1 Annual prevalence proportion of ADHD drug use in 2008 and
2012 among persons aged 18–64 years in the Nordic countries, by 1-year
age groups
Fig. 2 Annual prevalence proportion of ADHD drug use during 2008–
2012 among persons aged 18–64 years in the Nordic countries, by year
Fig. 3 Annual incidence of ADHD drug use during 2008–2012 among
persons aged 18–64 years in the Nordic countries, by year
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Type of ADHD drug used at treatment initiation
Methylphenidate was the preferred drug at treatment initiation
throughout the study period; 88 % of new users during 2008–
2012 received methylphenidate on the first prescription fill,
11 % received atomoxetine, whereas amphetamine and
dexamphetamine were rarely used (Fig. 4). In total, 38 % of
the new users received IR methylphenidate formulations and
49% received ER formulations. Therewas a shift towards using
ER formulations as first-line treatment during the study period.
These results were similar for the four age groups (data not
shown). Substantial differences were observed between coun-
tries, as about 70 % initiated treatment on IR formulations in
Denmark and Norway, whereas ER formulations were predom-
inantly used in the other countries (Online Resource Fig. S4).
Early discontinuation and switch in treatment
Among 62,144 new users of ADHD drugs during 2008–2011,
13% filled only the initial prescription and 9% filled only one
more prescription, while 79% filled 3 or more prescriptions of
any ADHD drug during the first year of treatment. When
restricting to users who initiated treatment on methylpheni-
date, 21 % filled only one or two prescriptions of any
ADHD drug during the first year (discontinuation), while
8 % received atomoxetine within the first year (switching).
Among users who initiated treatment on atomoxetine, 25 %
filled only one or two prescriptions while 32% receivedmeth-
ylphenidate within the first year.
Co-medication with other psychotropic drugs
Co-medication with other psychotropic drugs was common
among ADHD drug users in all age groups and both genders
(Table 1). Depending on gender and age category, 38–77% of
ADHD drug users received at least one other psychotropic
drug concurrently with their ADHD medication. Co-
medication was more common among older ADHD drug
users and higher among women than men. Antidepressants
were the most frequently used co-medication in all gender
and age categories, highest among 45–64-year-old women
(53 %). The proportion with co-medication was stable over
the study period (data not shown).
Discussion
This multinational study provides a detailed overview of
ADHD drug utilization among the entire adult population of
the five Nordic countries. Use of ADHD drugs more than
doubled during the 5-year study period, with 5.3 per 1000
men and 4.4 per 1000 women filling a prescription in the
last year of the study. One in five patients discontinued
ADHD drug use within the first year of treatment initiation.
Co-medication with other psychotropics among users of
ADHD drugs was common.
Strengths and limitations
This study utilises data from high-quality prescription regis-
ters with mandatory reporting that cover the entire population
of the Nordic countries [27]. Our results may slightly
underestimate ADHD drug use, as the prescription registers
do not include information on drugs administered in hospitals
or institutions. The Finnish prescription register only covers
reimbursed prescriptions and includes most prescriptions for
ADHD drugs. However, during March 2011–March 2012,
methylphenidate was not reimbursed for patients over
30 years. This may explain the slight dip in prevalence and
incidence observed for Finland (Online Resource Figs. S2 and
S3) but has little impact on the Nordic figures. Further, cov-
erage for hypnotics is incomplete because melatonin is not
reimbursable in Finland (Online Resource Table S2).
Differences in licencing and reimbursement of psychotropic
drugs and melatonin may impact the comparison of co-
medication between countries. A limitation is the lack of in-
formation on the underlying ADHD diagnosis, which pre-
cludes solid conclusions on appropriateness of treatment.
Licencing of ADHD drugs and types of drugs used
Licencing of ADHD drugs for use also in adults may partly
explain the substantial increase in use observed in the
present study. Methylphenidate has been extensively used
in the treatment of ADHD in children and adolescents
[14, 23, 25, 26, 30–32]. Over time, the labelling status for
prescribing these drugs to both children and adults has varied
between the Nordic countries. Continuation of atomoxetine
Fig. 4 Type of ADHD drug used at treatment initiation during 2008–
2012 among persons aged 18–64 years in the Nordic countries, by year.
IR immediate release formulation, ER extended release formulation
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treatment from childhood into adulthood was approved in
Nordic countries in 2005, while continuation of methylpheni-
date treatment was approved from 2011 in some Nordic coun-
tries. After the study period of the present study (2008–2012),
initiation of drug therapy in treatment-naïve adults has been
approved for atomoxetine, methylphenidate and the new sub-
stance lisdexamphetamine.
Guidelines that also focus on the management of adult
ADHD have only recently been published in all Nordic coun-
tries but Finland, stating that methylphenidate is first-line
treatment while atomoxetine is second-line treatment
[16–19]. Our study finds that methylphenidate was the pre-
ferred drug in both prevalent and new users as 9 of 10 patients
used it. Use of atomoxetine remained limited, and
dexamphetamine and amphetamine were rarely used. This
differs markedly from the USA, where amphetamine and
dexamphetamine formulations are used by a substantial pro-
portion of adult patients [23, 31, 32]. Our study further re-
vealed that the use of ER formulations of methylphenidate
increased while IR formulations decreased. The ER formula-
tion has the advantage of once-daily administration, which
may be advantageous given the clinical manifestation of
ADHD.
Prevalence and incidence of ADHD drug use
The present study reveals a markedly increased prevalence of
ADHD drug use during 2008–2012. However, the preva-
lences reported in the present study (2.1 per 1000 in 2008,
4.9 per 1000 in 2012) are substantially lower than what has
been observed in the USA (12 per 1000 aged 20 years or older
in 2005) [23], and higher than in the United Kingdom (1.1 per
1000 aged 18–24 years and 0.07 per 1000 aged 25–45 years in
2008) [24]. Differences in data source, the patient population
under study and the definitions of drug use applied in each
analysis may explain some of this geographical variation.
Nevertheless, we found substantial difference in utilization
patterns within the Nordic countries despite leveraging similar
and nationwide data in five neighbouring countries, with sim-
ilar healthcare systems and social structures, and used one
programme for data analysis. Similarly, large variations have
previously been observed between regions within the individ-
ual countries [33, 34]. These geographical variations in use
point towards differences in guidelines [35], as well as pre-
scribing practice and tradition being the most important pa-
rameters underlying the observed variations.
The prevalence of ADHD drug use increased substantially
during the study period and was 4.9 per 1000 in 2012.
Nevertheless, it is lower than the reported prevalence of the
ADHD diagnosis, ranging from 10 to 80 per 1000 [6, 9,
12–14]. Our results also showed that the incidence of drug
use increased, but to a lesser extent in the last part of the study
period. Thus, the proportion of adults with ADHD not receiv-
ing pharmacological treatment may remain high. We found
that drug use was more common in men than women, but
the gender ratio was smaller than observed among children
in the Nordic countries [30] and internationally [24, 26, 36].
The gender ratio for prescribing of ADHD drugs for adults in
the UK is substantially higher than in the present study [24]. A
diminishing gender difference from childhood to adulthood is
in line with the reported differences by gender for diagnosis of
ADHD [8].
Early discontinuation and switch in treatment
Our results indicate that 21 % of persons who initiated treat-
ment had discontinued all ADHD drugs within the first year.
Other studies have revealed higher levels of discontinuation in
adults [37–40]. Continuity of drug treatment may be compro-
mised when patients transition from the adolescent health and
Table 1 Proportion (%) of ADHD drug users with co-medication of other psychotropic drugs in 2012 among persons aged 18–64 years in the Nordic
countries
Gender Men Women
Age group 18–24 25–34 35–44 45–64 18–64 18–24 25–34 35–44 45–64 18–64
ADHD users (n) 14,396 11,972 9059 7023 42,450 10,693 9478 8210 6065 34,446
Any psychotropic 38 56 62 67 53 50 65 71 77 64
Antidepressants 20 32 37 40 30 32 44 49 53 43
Antiepileptics 7 15 16 17 13 10 17 19 21 16
Antipsychotics 14 20 20 19 18 13 18 18 19 17
Anxiolytics 7 17 21 25 16 13 23 26 32 22
Hypnotics 15 23 27 31 23 22 29 33 40 30
Melatonin 7 6 5 5 6 8 7 8 7 8
Other hypnotics 10 20 24 29 19 15 25 29 36 25
Proportion (%) of ADHD drug users with co-medication, defined as filling a prescription for other psychotropic drugs within 3 months before or after
filling a prescription for an ADHD drug (i.e. concomitant use)
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social care systems to the adult system [10, 41], and some
physicians may be reluctant to prescribe ADHD drugs to
adults [1, 2, 4, 8]. We observed a higher proportion of early
discontinuation and drug switching among users who initiated
treatment with atomoxetine than those initiating treatment
with methylphenidate. As atomoxetine is not considered
first-line treatment [16–19], patients initiated directly on
atomoxetine may differ from the overall study population,
e.g. with respect to liability for substance misuse. Also,
stricter regulation of substances classified as narcotics
(methylphenidate) may lead to shorter supply per methylphe-
nidate prescription, thus requiring more frequent prescription
fills for methylphenidate than atomoxetine. Further studies
should elucidate the long-term treatment duration and switch
patterns for ADHD drugs.
Co-medication of other psychotropic drugs with ADHD
drugs
Studies of epidemiological and clinical populations of adults
with ADHD have revealed that comorbid psychiatric illnesses
are very common, in particular depression and substance use
disorders [6, 8, 9, 15]. In the present study, antidepressants
were the most frequently used psychotropic among users of
ADHD drugs, with as many as half of the women over
34 years receiving antidepressants. Hypnotics were also com-
monly used, with the Z-hypnotics, such as zopiclone, pre-
ferred over melatonin. The presence of comorbidities poses
additional challenges for diagnosis and treatment management
of ADHD and may affect both the initiation and continuation
of ADHD treatment [6, 15]. Evidence for the efficacy and
safety of combined pharmacological treatment of ADHD
and other psychiatric illnesses is limited.
Unanswered questions
The present study did not reveal to what extent persons receiv-
ing pharmacological treatment with ADHD drugs also had a
diagnosis for ADHD or other psychiatric illnesses, or vice
versa. There is generally less evidence on the efficacy and
safety for ADHD drugs in adults than in children, which is
of concern given the substantially higher rates of comorbid
psychiatric and somatic disorders in the adult population.
For instance, ADHD drugs have been linked to a moderate
increase in heart rate and blood pressure although evidence
does not point to increased rate of serious cardiovascular
events [42–45]. The Nordic countries provide an opportune
setting for studies on these and other unanswered questions
regarding outcomes of ADHD drug treatment in adults, with
several health registers covering the entire population in each
country and the possibility to track the exposures and out-
comes of all persons over time [27].
Conclusion
The present study revealed that the use of ADHD drug among
adults more than doubled over a 5-year period, and a majority
were concurrently treated with other psychotropics. Because
of these recent developments in ADHD drug use patterns,
adults now constitute about half of the persons using ADHD
drugs in the Nordic countries. Thus, evidence for long-term
treatment efficacy and safety in adults is urgently needed.
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